Table 2 Expression of the KIF20A gene in pancreatic cancer and various malignancies investigated by cDNA microarray analysesa

From: Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer

  N Positive ratea (%) Average of relative expression ratio
Pancreatic cancer 6/6 100 31 900
Small cell lung cancer 15/15 100 22
Bladder cancer 30/31 97 20 500
Non-small cell lung cancer 20/22 91 25 800
Cholangiocellular carcinoma 7/11 64 3 780
Breast cancer 29/61 44 322
Prostate cancer 11/36 31 4
Renal cell carcinoma 3/11 27 5
Oesophageal cancer 2/13 15 3
Colorectal cancer 2/31 3 2
Gastric cancer 0/4 0 0
  1. Data are obtained from our previous studies (Nakao et al, 1995; Uchida et al, 2004; Yoshitake et al, 2004; Taniuchi et al, 2005; Watanabe et al, 2005).
  2. aThe relative expression ratio was calculated by dividing the value of the expression of KIF20A mRNA in cancer cells by that in the normal counterpart, and a relative expression ratio (cancer/normal tissue) of >5 was considered to be positive.